ASCO 2019 Breakfast Brief – Lung cancer
In this Breakfast Brief Prof. Dr. Solange Peters, Central University Hospital (CHUV) in Lausanne, presents new and noteworthy trials dominating current discussions in lung cancer.
Video Contents00:00 Lack of new phase III trials, but many updates to immunotherapy and targeted therapies 00:50 Keynote-001: lessons to learn from long term survivors 02:47 Keynote-189: strong benefit irrespective of PD-L1 03:54 Biomarker: PD-L1 expression differs in every organ, bone or tissue influencing the predictive outcome 05:45 MYSTIC: bTMB as predictive biomarker for OS with Durvalumab ± Tremelimumab vs chemotherapy 06:32 Targeted therapies for rare entities are numerous in phase I and II and work well with acceptable toxicities 07:45 The new RET-Inhibitors on the block: LOXO-292, BLU-667 08:15 Reponectrinib: the next-generation ROS1/TRK/ALK TKI 08:45 New potent MET Exon 14 inhibitors: tepotinib, catnitinib 09:22 Antitumour activity is also shown for TAK-788 in NSCLC with EGFR exon 20 insertions 09:42 Dual blockade of EGFR and VEGFR pathways for the first line 11:45 JNJ 372: an extremely promising EGFR and cMET blocker 12:38 U3-1402: a treatment option for EGFRm NSCLC resistant to EGFR TKIs 13:20 The combination of bevacizumab and pemetrexed cannot be recommended as maintenance
More from this topic:
ASCO 2019: Durable responses in patients with melanoma brain metastases with nivolumab/ipilimumab
11. 06. 2019
ASCO 2019: Pembrolizumab facilitates previously unmet 5-year-overall survival for NSCLC
06. 06. 2019